US Patent 7910598 Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
Patent 7910598 was granted and assigned to Natco Pharma on March, 2011 by the United States Patent and Trademark Office.
All edits
The present invention relates to novel intermediates useful for the preparation of novel phenylaminopyrimidine derivatives, novel phenylaminopyrimidine derivatives. Pharmaceutical composition containing the novel phenylaminopyrimidine derivatives and processes for their preparation. The invention particularly relates to novel Phenyl pyrimidine amine derivatives of the general formula (I). The novel compounds of the formula 1 can be used in the therapy of Chronic Myeloid Leukemia (CML). Since the IC50; 191 values of these molecules are in the range 0.1 to 10.0 nm, these novel compounds are potentially useful for the treatment of CML.
US Patent 07910598 Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase US Patent 7910598 Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
US Patent 07910598 Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
Find more entities like US Patent 7910598 Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
